Functional characterization of Musca glutamate- and GABA-gated chloride channels expressed independently and coexpressed in Xenopus oocytes. 2006

Y Eguchi, and M Ihara, and E Ochi, and Y Shibata, and K Matsuda, and S Fushiki, and H Sugama, and Y Hamasaki, and H Niwa, and M Wada, and F Ozoe, and Y Ozoe
Department of Applied Biological Chemistry, Faculty of Agriculture, Kinki University, Nara, Japan.

Ligand-gated chloride channels (LGICs) are important targets for insecticides and parasiticides. Genes encoding subunits of two LGICs, a glutamate-gated chloride channel (MdGluCl-alpha) and a gamma-aminobutyric acid (GABA)-gated chloride channel (MdRdl), were cloned from house-flies (Musca domestica L.). These genes were first expressed independently in Xenopus laevis oocytes by cRNA injection in order to investigate the pharmacology of these ligand-gated channels using two-electrode voltage-clamp electrophysiology. It was found that L-glutamate and GABA activated the MdGluCl-alpha homo-oligomers with an EC(50) value of 30 microM and the MdRdl homo-oligomers with an EC(50) value of 101 microM, respectively. Both channels were chloride ion-permeable, and the MdRdl channel was more sensitive to chloride channel blockers, such as gamma-hexachlorocyclohexane (gamma-HCH), fipronil and picrotoxinin, than the MdGluCl-alpha channel. MdGluCl-alpha required only 1-2 days of incubation after cRNA injection to be expressed in oocytes, whereas 4-7 days of incubation was necessary to achieve MdRdl expression. However, when the cRNA of MdGluCl-alpha was injected at a dose of 1% (w/w) 1 day after the injection of the cRNA of MdRdl, a significant increase in the current amplitude of responses to GABA was observed, and the incubation period necessary for MdRdl expression became shorter. These results suggest that MdGluCl-alpha assists in the expression of MdRdl when the two are coexpressed.

UI MeSH Term Description Entries
D009117 Muscidae A family of the order DIPTERA with over 700 species. Important species that may be mechanical vectors of disease include Musca domesticus (HOUSEFLIES), Musca autumnalis (face fly), Stomoxys calcitrans (stable fly), Haematobia irritans (horn fly) and Fannia spp. Face Fly,Fannia,Haematobia irritans,Horn Fly,Musca autumnalis,Stable Fly,Stomoxys calcitrans,Face Flies,Fannias,Flies, Face,Flies, Horn,Flies, Stable,Fly, Face,Fly, Horn,Fly, Stable,Haematobia irritan,Horn Flies,Musca autumnali,Stable Flies,Stomoxys calcitran,autumnali, Musca,calcitran, Stomoxys,irritan, Haematobia
D009865 Oocytes Female germ cells derived from OOGONIA and termed OOCYTES when they enter MEIOSIS. The primary oocytes begin meiosis but are arrested at the diplotene state until OVULATION at PUBERTY to give rise to haploid secondary oocytes or ova (OVUM). Ovocytes,Oocyte,Ovocyte
D010852 Picrotoxin A mixture of PICROTOXININ and PICROTIN that is a noncompetitive antagonist at GABA-A receptors acting as a convulsant. Picrotoxin blocks the GAMMA-AMINOBUTYRIC ACID-activated chloride ionophore. Although it is most often used as a research tool, it has been used as a CNS stimulant and an antidote in poisoning by CNS depressants, especially the barbiturates. 3,6-Methano-8H-1,5,7-trioxacyclopenta(ij)cycloprop(a)azulene-4,8(3H)-dione, hexahydro-2a-hydroxy-9-(1-hydroxy-1-methylethyl)-8b-methyl-, (1aR-(1aalpha,2abeta,3beta,6beta,6abeta,8aS*,8bbeta,9S*))-, compd. with (1aR-(1aalpha,2abeta,3beta,6beta,6abeta,8,Cocculin
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005680 gamma-Aminobutyric Acid The most common inhibitory neurotransmitter in the central nervous system. 4-Aminobutyric Acid,GABA,4-Aminobutanoic Acid,Aminalon,Aminalone,Gammalon,Lithium GABA,gamma-Aminobutyric Acid, Calcium Salt (2:1),gamma-Aminobutyric Acid, Hydrochloride,gamma-Aminobutyric Acid, Monolithium Salt,gamma-Aminobutyric Acid, Monosodium Salt,gamma-Aminobutyric Acid, Zinc Salt (2:1),4 Aminobutanoic Acid,4 Aminobutyric Acid,Acid, Hydrochloride gamma-Aminobutyric,GABA, Lithium,Hydrochloride gamma-Aminobutyric Acid,gamma Aminobutyric Acid,gamma Aminobutyric Acid, Hydrochloride,gamma Aminobutyric Acid, Monolithium Salt,gamma Aminobutyric Acid, Monosodium Salt
D005971 Glutamates Derivatives of GLUTAMIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the 2-aminopentanedioic acid structure. Glutamic Acid Derivatives,Glutamic Acids,Glutaminic Acids
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000977 Antiparasitic Agents Drugs used to treat or prevent parasitic infections. Antiparasitic,Antiparasitic Agent,Antiparasitic Drug,Parasiticide,Parasiticides,Antiparasitic Drugs,Antiparasitics,Agent, Antiparasitic,Agents, Antiparasitic,Drug, Antiparasitic,Drugs, Antiparasitic

Related Publications

Y Eguchi, and M Ihara, and E Ochi, and Y Shibata, and K Matsuda, and S Fushiki, and H Sugama, and Y Hamasaki, and H Niwa, and M Wada, and F Ozoe, and Y Ozoe
September 2013, Journal of insect physiology,
Y Eguchi, and M Ihara, and E Ochi, and Y Shibata, and K Matsuda, and S Fushiki, and H Sugama, and Y Hamasaki, and H Niwa, and M Wada, and F Ozoe, and Y Ozoe
January 1995, Masui. The Japanese journal of anesthesiology,
Y Eguchi, and M Ihara, and E Ochi, and Y Shibata, and K Matsuda, and S Fushiki, and H Sugama, and Y Hamasaki, and H Niwa, and M Wada, and F Ozoe, and Y Ozoe
July 2008, The Journal of pharmacology and experimental therapeutics,
Y Eguchi, and M Ihara, and E Ochi, and Y Shibata, and K Matsuda, and S Fushiki, and H Sugama, and Y Hamasaki, and H Niwa, and M Wada, and F Ozoe, and Y Ozoe
January 2020, Methods in molecular biology (Clifton, N.J.),
Y Eguchi, and M Ihara, and E Ochi, and Y Shibata, and K Matsuda, and S Fushiki, and H Sugama, and Y Hamasaki, and H Niwa, and M Wada, and F Ozoe, and Y Ozoe
November 2012, The Journal of biological chemistry,
Y Eguchi, and M Ihara, and E Ochi, and Y Shibata, and K Matsuda, and S Fushiki, and H Sugama, and Y Hamasaki, and H Niwa, and M Wada, and F Ozoe, and Y Ozoe
January 2003, Archives of pharmacal research,
Y Eguchi, and M Ihara, and E Ochi, and Y Shibata, and K Matsuda, and S Fushiki, and H Sugama, and Y Hamasaki, and H Niwa, and M Wada, and F Ozoe, and Y Ozoe
August 1998, European journal of pharmacology,
Y Eguchi, and M Ihara, and E Ochi, and Y Shibata, and K Matsuda, and S Fushiki, and H Sugama, and Y Hamasaki, and H Niwa, and M Wada, and F Ozoe, and Y Ozoe
May 2017, Neurotoxicology,
Y Eguchi, and M Ihara, and E Ochi, and Y Shibata, and K Matsuda, and S Fushiki, and H Sugama, and Y Hamasaki, and H Niwa, and M Wada, and F Ozoe, and Y Ozoe
January 1997, Neuropharmacology,
Y Eguchi, and M Ihara, and E Ochi, and Y Shibata, and K Matsuda, and S Fushiki, and H Sugama, and Y Hamasaki, and H Niwa, and M Wada, and F Ozoe, and Y Ozoe
November 2012, Pharmacology, biochemistry, and behavior,
Copied contents to your clipboard!